Biotech Catalyst Intelligence

Track biotech catalysts before the market reacts

Monitor FDA dates, trial milestones, dilution signals, short interest, insider trades, and sentiment in one focused workflow.

Catalyst Calendar Dilution Risk Engine Daily AI Brief Insider Tracking Short Squeeze Data
bioradar / dashboard
VKTXViking Therapeutics
$38.42 +8.7%
◆ AI Daily Brief
VK2735 Phase 3 VENTURE trial enrollment accelerating; topline data H2 2026
$943M cash on hand — runway extends through Phase 3 completion
Short interest at 11.8% with institutions adding; buyout speculation rising
Cash Runway
36+ mo
$943M cash · $52M burn
Squeeze Score
72 / 100
SI 11.8% · 3.2 DTC
Dilution Risk
Low Risk
$943M cash, 36+ mo runway
Phase 3 Catalyst
VENTURE Trial
VK2735 obesity · topline H2 2026
Short Interest
11.8% of float
Rising · 3.2 days to cover
Institutional Flow
+340% Q4
Citadel, Vanguard adding
FDA Dates
Phase Catalysts
Dilution Alerts
Short Interest
Insider Activity
Sentiment Tracking

Signals that actually move biotech stocks

Biotech doesn't move on fundamentals. It moves on events, filings, and fear. Miss one signal and you miss the trade.

Catalysts create the move

FDA PDUFA dates, Phase 2/3 readouts, and NDA submissions drive 50-300% moves in small-cap biotech. Missing the date means missing the setup.

Dilution kills the upside

ATM offerings, shelf registrations, and low cash runway are the silent killers. Track burn rate and offering risk before it blindsides your position.

Sentiment shifts fast

A single FDA tweet can flip sentiment overnight. Monitor Reddit buzz, news flow, and bullish/bearish shifts in real time across biotech communities.

Smart money leaves clues

Insider purchases at $1.50 before a catalyst? Institutions quietly building a position? These signals exist in SEC filings. We surface them for you.

Everything in one workflow

Catalyst Calendar

Never miss an FDA date or trial milestone again

PDUFA target dates, Phase 2/3 data readouts, ASCO presentations, and earnings calls — all tracked with countdown timers and importance rankings.

  • FDA PDUFA and NDA action dates
  • Phase 2b/3 interim and final readouts
  • Conference presentations and earnings
  • Days-until countdown with urgency flags
◆ Upcoming Catalysts — VKTX
22 Mar
PHASE 3
VENTURE Trial Enrollment Update
VK2735 oral obesity trial enrollment milestone
6 DAYS
15 May
EARNINGS
Q1 2026 Earnings + Pipeline Update
Expected cash burn disclosure and trial progress
60 DAYS
Q3 2026
PHASE 3
VENTURE Topline Data Readout
Primary endpoint: % body weight loss vs placebo
~180 DAYS
Dilution Risk Engine

Spot dilution risk before it blindsides your trade

Cash runway gauge, burn rate tracking, ATM offering detection, and dilution warnings. Know exactly when a company is running low on cash and likely to raise.

  • Cash runway in months with risk level
  • ATM offering detection from SEC filings
  • Dilution percentage calculations
  • Risk dashboard: green / caution / danger
◆ Risk Dashboard — VKTX
Cash on Hand $943M
Quarterly Burn $52M
Cash Runway 36+ MONTHS — SAFE
Recent Offering NONE — FULLY FUNDED
Buyout Speculation Pfizer, Amgen rumored
Short Interest 11.8%
AI Intelligence Layer

Daily AI brief and real-time sentiment tracking

Every morning, get a 3-bullet summary of what matters for each ticker. Throughout the day, track Reddit buzz, news sentiment, and volume anomalies as they happen.

  • Daily AI TL;DR with key events
  • Reddit buzz tracking across biotech subs
  • News headlines with sentiment scoring
  • Email alerts on spike conditions
◆ AI Daily Brief — VKTX — Today
VK2735 Phase 3 VENTURE trial enrollment on track; oral formulation could differentiate from Lilly/Novo
$943M cash runway through Phase 3 completion — no dilution risk. Buyout speculation increasing
Short interest at 11.8% with 3.2 DTC; institutions added $420M in Q4 filings
◆ Latest News
Viking surges as analysts raise PT to $52 BULLISH
Pfizer acquisition rumors resurface on Street BULLISH
GLP-1 competition intensifies as Amgen posts data BEARISH
Drug Pipeline & Drug IQ

Understand every drug in the pipeline — and why it matters

See every drug a company is developing, its phase, indication, and enrollment status. Drug IQ cards explain the mechanism of action, competitive landscape, and market opportunity in plain English.

  • Full drug pipeline from ClinicalTrials.gov
  • Drug IQ cards: mechanism, competition, market size
  • Enrollment progress tracker with timeline bars
  • Phase context: probability of approval at each stage
◆ Drug Pipeline — VKTX
VK2735 PHASE 3 Recruiting Obesity
VK2809 PHASE 2 Completed NASH
VK5211 PHASE 2 Completed Hip Fractures
DRUG IQ — VK2735
GLP-1/GIP Dual Agonist
Activates both GLP-1 and GIP receptors, reducing appetite and increasing insulin sensitivity. Dual mechanism may provide superior weight loss vs semaglutide.
Event Calendars

PDUFA dates, earnings, and conferences — all in one place

Three dedicated calendars track every market-moving event. FDA approval dates from SEC filings, quarterly earnings with EPS estimates, and 16 major biotech conferences with countdown timers.

  • PDUFA Calendar with 38+ FDA decision dates
  • Earnings Calendar with EPS/revenue estimates
  • Conference Calendar: ASCO, AACR, JPM, ASH & more
  • Filterable, searchable, with countdown badges
◆ Upcoming PDUFA Dates
Apr 3, 2026 BIIB NDA Alzheimer's 11d
Apr 13, 2026 TVTX NDA Metabolic 21d
Jul 11, 2026 CORT NDA Cushing's 110d

Built for event-driven biotech traders

Whether you're scalping a PDUFA run-up, avoiding a dilution trap, or monitoring a squeeze setup — BioRadar keeps you focused.

01

Build your watchlist

Add biotech tickers you're tracking. BioRadar immediately starts pulling catalyst dates, insider filings, short data, and sentiment for each one.

02

Track catalysts and risk

See upcoming FDA dates, trial readouts, cash runway status, and squeeze potential at a glance. The AI brief distills everything daily into 3 bullets.

03

Get alerts before key events

Receive email alerts when sentiment spikes, volume anomalies hit, insiders buy, or a catalyst date approaches. Know before the crowd moves.

BioRadar finds signals. Trade on eToro.

Spotted a setup? Open a position directly on eToro — the world’s leading social trading platform with 30M+ users and 3,000+ instruments.

Open eToro Account → Capital at risk. eToro is a multi-asset platform. Affiliate link.

Start free. Upgrade when you're ready.

Track 3 tickers for free. Unlock the full scanner, AI trade setups, and unlimited tickers with Premium.

Free
$0/mo
No credit card required
  • 3 watchlist tickers
  • Sentiment analysis
  • Price & volume tracking
  • Insider trading data
  • Short interest data
Create Free Account →
Premium
$15/mo
Cancel anytime · Powered by Stripe
  • Everything in Free, plus:
  • BioRadar Scanner (130+ stocks)
  • AI Trade Setups (entry/stop/target)
  • Unlimited watchlist tickers
  • Email alerts on all signals
  • Cash runway & squeeze scoring
  • PDUFA Calendar + Earnings Calendar
  • Drug Pipeline & Drug IQ cards
  • Enrollment Tracker + Conference Calendar
Start Free & Upgrade Later →

Track biotech catalysts
with less noise

FDA dates, dilution risk, sentiment, insider activity — one focused workflow for biotech traders.

Start Free Trial →

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.